Piper Jaffray analyst Sean Wieland believes Teladoc’s “solid” Q1 results rebuffed the “multiple overhangs” on the stock. Strong utilization trends brushed off the concerns over the weak flu season and management committed to receiving the NCQA accreditation, Wieland tells investors in a research note. He sees new or expansion opportunities for the company across United, Aetna, Tricare, and the Medicare Advantage markets. As such, the analyst reiterates an Overweight rating on the shares with an $86 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.